Sun Pharma shares rise as Q2 profit falls 36.4%
In short
Sun Pharma shares rose 0.87% after the company reported September-quarter profit of ₹1,988.5 crore, down 36.4% from a year earlier. Revenue still grew 11.9% to ₹16,198.7 crore.
The company said India and innovative medicines helped sales, while US litigation and Organon acquisition costs hurt profit. The report does not say the final share price or whether analysts turned more positive or negative.
What the reporting says
Sun Pharma shares rose 0.87% even as the company reported a 36.4% year-on-year drop in September-quarter net profit to ₹1,988.5 crore. Revenue increased 11.9% to ₹16,198.7 crore, helped by India and innovative medicines, while exceptional US litigation and Organon acquisition costs weighed on earnings. The report does not say whether the stock move held through the session or how brokers ultimately rated the shares.
Why it matters
Sun Pharma’s shares gained 0.87% after the company posted a September-quarter net profit of ₹1,988.5 crore, down 36.4% year on year, even as revenue rose 11.9% to ₹16,198.7 crore. The summary attributes the earnings pressure to exceptional US litigation and Organon acquisition costs, while India and innovative medicines supported sales. The report does not provide the brokerage view or final trading reaction.